CatalYm GmbH

CatalYm GmbH is a biopharmaceutical company located in Planegg, Bayern, Germany. Founded in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg, the company focuses on developing innovative cancer immunotherapies. Its primary product is visugromab, a monoclonal antibody targeting Growth-and-Differentiation Factor 15 (GDF-15). This therapy aims to overcome resistance to cancer treatments and enhance the effectiveness of existing immunotherapies, particularly for patients with high unmet medical needs. The leadership team includes CEO Scott Clarke, who has extensive experience in the biopharmaceutical industry, and CFO Anne Burger, known for her expertise in financial operations and fundraising. CatalYm is supported by several international venture capital investors and receives backing from the European Investment Fund. The company's research emphasizes understanding GDF-15's role in immunosuppression within tumors, aiming to provide new treatment options for patients facing limited therapeutic choices.

Research Planegg, Germany ~3 employees Private · Series D

Work at CatalYm GmbH in HR or recruiting? Claim this page

Employees
3
+50% in the 3 months to Jun 2025
Revenue / employee
$667K
Revenue ~$2M
Total funding
$258M
Last round Series D, Jul 2024
12-month attrition
70.6%
H1B sponsor
NA

Headcount trend

CatalYm GmbH went from 0 employees in Jul 2023 to 3 in Jun 2025. Jan to Jun 2025: 2 people joined, 0 left.

Headcount data through Jun 2025

Funding rounds

Total funding$258M
Funding rounds5
Investors16

Org structure

Headcount by department

Other2
Operations1

CatalYm GmbH FAQ

How many employees does CatalYm GmbH have?

CatalYm GmbH has about 3 employees, up 50% over the 3 months to Jun 2025.

What is CatalYm GmbH's revenue per employee?

CatalYm GmbH makes about $667K in revenue per employee, based on $2M annual revenue and 3 employees.

How much funding has CatalYm GmbH raised?

CatalYm GmbH has raised $258.31M in total funding; its latest round was Series D in Jul 2024.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.